Tag Archives: birth

Non-inferior cardiovascular outcome for DPP-4 inhibitor Results from the CAROLINA cardiovascular outcome study show that the DPP-4 inhibitor linagliptin (Trajenta®, Boehringer Ingelheim and Eli Lilly) is non-inferior to the sulphonylurea glimepiride in the treatment of adults with type 2 diabetes and cardiovascular risk. The study met its primary end point – defined as the non-inferiority of linagliptin versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The study, carried out over six years in 6,033 adults with type 2 diabetes and increased cardiovascular risk or est